ERBB2 and breast carcinoma: Previous in vitro and in vivo studies have shown that cytokines such as IL-2, IL-12, IL-15 and interferon can enhance the effect of antibody-ADCC for immunotherapy of cancer, e.g., IL-2 and IL-15 enhanced NK cell response to Herceptin-coated Her2/neu+ breast cancer cells in vitro [54].